Biotronik reports positive data from Pulsar stent trial

Biotronik has reported data from 4Ever, a new clinical study assessing the benefits its Pulsar self-expanding stent system provides for superficial femoral artery patients.

Results taken after 12 months demonstrated the efficacy and safety of the device, in terms of its ability to provide excellent primary patency and freedom from target lesion revascularisation.

Pulsar stents offer an innovative and flexible design and are coated with Probio, a silicon carbide layer that improves its haemocompatibility and biocompatibility.

It is thought that the advantages of the device will be even more readily apparent when 24-month data from this trial is presented.

Alain Aimonetti, vice-president for sales and business development at Biotronik's vascular intervention division, said: "The 4Ever results strongly suggest that Pulsar stent systems with optimal radial force combined with high flexibility are superior to systems which concentrate mainly on high radial force in treating SFA disease."

This comes after the firm expanded its portfolio with the launch of the new 3Flow Aspiration Catheter earlier this month.